These states are national leaders when it comes to driving 21st century forward. Today, we're looking at tech leaders across ...

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Spotify appeared to be experiencing a widespread technical issues Wednesday morning — with tens of thousands of users ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Mayoral candidate Scott Stringer is proposing a new zoning designation to block President Donald Trump from auctioning off federal buildings to luxury developers, the Daily News has ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer. The infused treatment from Japanese drugmaker Eisai and ...

“Had a little assist there, so thank you.” William Byron, who began on the pole and dominated the first 243 laps, finished second. Christopher Bell, Reddick and Blaney rounded out the top fiv ...

Biogen Inc. has a one year low of $122.77 and a one year high of $238.00. The company has a market cap of $18.00 billion, a PE ratio of 10.99, a P/E/G ratio of 1.51 and a beta of 0.01.

During the last three months, 14 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Brain health has emerged as one of the defining challenges of our time, driven by a double whammy of soaring rates of ...